Arcutis to Unveil Late-Breaking Phase 2 Infant ZORYVE 0.05% Data at AAD
Arcutis will present late-breaking Phase 2 data from its INTEGUMENT-INFANT trial of once-daily ZORYVE cream 0.05% in infants aged 3–24 months with mild to moderate atopic dermatitis at the AAD Annual Meeting March 27–31 in Denver. Posters will detail caregiver outcomes in 2–5-year-olds and psoriasis subgroups.
1. Late-Breaking Podium Presentation
Arcutis will present late-breaking podium data from its Phase 2 INTEGUMENT-INFANT trial evaluating once-daily ZORYVE cream 0.05% in infants aged three to 24 months with mild to moderate atopic dermatitis at the AAD Annual Meeting in Denver, underscoring key efficacy, safety and tolerability findings.
2. Additional Poster Highlights
A five-minute poster will showcase long-term caregiver-reported outcomes from the Phase 3 INTEGUMENT-OLE trial in children aged two to five, while two electronic posters will detail subgroup efficacy in seborrheic dermatitis (STRATUM trial) and PASI outcomes in plaque psoriasis (DERMIS-1/2 and ARRECTOR trials).
3. Strategic Implications
These presentations could support pediatric label expansion of ZORYVE formulations and strengthen Arcutis’ leading portfolio across atopic dermatitis, seborrheic dermatitis and plaque psoriasis, potentially driving prescription volume growth and market share gains.